Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Only 43% of community oncologists feel very comfortable with new immunotherapies. Prerna Mewawalla, M.D., of Allegheny Health Network talks safety protocols and trial access.
Among 16 Black transgender women, 15 with HIV, risk awareness, comfort, provider trust and support shaped whether they completed HRA, according to a new qualitative study.
A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.